Please login to the form below

Not currently logged in
Email:
Password:

Genmab

This page shows the latest Genmab news and features for those working in and with pharma, biotech and healthcare.

Xencor’s Novartis-partnered bispecific on hold after patient deaths

Xencor’s Novartis-partnered bispecific on hold after patient deaths

also placed on full clinical hold after a death and two life-threatening events, while in July 2018 Genmab/Johnson &Johnson’s CD3/CD123 bispecific JNJ-63709178 was placed under clinical

Latest news

More from news
Approximately 5 fully matching, plus 36 partially matching documents found.

Latest Intelligence

  • Deal Watch August 2016 Deal Watch August 2016

    469. Genmab (DK). Gilead (US). Licence. DuoBody technology platform to develop bispecific antibody candidates for targeting HIV plus option to second licence.

  • Pharma deals in August 2015 Pharma deals in August 2015

    Exclusive global licence. 510. Genmab. Novo Nordisk. Bispecific antibody candidates outside oncology indications.

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    244. Seattle Genetics / Genmab. Licence and collaboration. Additional deal to use Seattle's antibody drug conjugate technology.

  • Pharma deals during September 2014 Pharma deals during September 2014

    Four years ago Genmab started working with Seattle Genetics' ADC technology and has now signed a new deal using a Genmab antibody. The creative aspect of this deal is that Seattle ... has retained an option to increase the Genmab royalties to double

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    Genmab/ Janssen. Milestone payment. Daratumumab, anti-CD38 mAb for multiple myeloma (p2 milestone).

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • EUSA Pharma appoints Rolf Hoffmann to its board EUSA Pharma appoints Rolf Hoffmann to its board

    Hoffman, who is currently chairman of Biotest and sits on the board of directors of Genmab, brings over 30 years’ pharmaceutical experience to his new position having served in a number

  • Dr Jan van de Winkel joins Austrian biotech Hookipa Dr Jan van de Winkel joins Austrian biotech Hookipa

    Current president and chief executive officer of Genmab, Dr van de Winkel joins the board with over 25 years’ experience in the therapeutic antibody field. ... Dr van de Winkel’s career experience has seen him serve Medarex Europe as its vice

  • Former Novartis exec joins Genmab Former Novartis exec joins Genmab

    Dr Judith Klimovsky becomes chief development officer. Copenhagen, Denmark-based Genmab has appointed Dr Judith Klimovsky as executive vice president and chief development officer. ... Jan van de Winkel, Genmab's chief executive, said: “We are very

  • bmore creative hires Kush Rach as new business director bmore creative hires Kush Rach as new business director

    at Charles River Laboratories, where he worked on clinical trial programmes for Ferring, Genmab, AstraZeneca, and Aerocrine (spending much of his time in Scandinavia).

  • Agneta Svedberg appointed COO at Zealand Pharma Agneta Svedberg appointed COO at Zealand Pharma

    Svedberg has more than 20 years of experience in the industry, most of which has been spent in northern Europe and includes a ten-year spell with Genmab in Denmark, where

More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics